本帖最后由 老马 于 2013-3-13 13:43 编辑 / k, o5 Z: g0 |1 t; @: m. J7 `
1 G0 q# o# |4 o7 B: R7 T
健择（吉西他滨）+顺铂+阿瓦斯汀
: L0 B% q) J" k d Gemzar +Cisplatin + Avastin
- B4 h7 z6 B* `9 Qhttp://annonc.oxfordjournals.org/content/21/9/1804.full9 j7 F8 S' V# ]
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ( `" H- ]% T$ u7 Q
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
- X+ C# ]$ F9 n+ c1 M) L7 N: dResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
! @8 d1 i+ K. T8 @( r
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1014)
) {% R# I$ u S' g. ]
华为网盘附件：
0 m; B) D1 S. x' C4 y" ^' d【华为网盘】ava.JPG
! H' S* C' M0 ~+ s; B* c |
显身卡
